This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "gout_urate_crystal_inflammation#NLRP3 Inflammasome Activation"). The module defines the expected pathophysiology structure; conforming nodes in disorder files should include the corresponding cell types, biological processes, and causal edges, specialized to their disease context. Key disease-specific substitutions: primary gout uses transporter-mediated urate underexcretion (URAT1/ABCG2); enzymatic overproduction syndromes (e.g., HPRT1 deficiency / Lesch-Nyhan, PRPP synthetase superactivity) substitute the overproduction driver at the trigger node. Urate chemistry is described in prose only; modules bind GO and CL terms only and do not use chemical (CHEBI) term bindings.
Hyperuricaemia
trigger
Serum urate rises above its physiological solubility limit owing to urate overproduction (increased purine turnover and xanthine oxidoreductase activity) and/or underexcretion. Renal and intestinal urate handling by membrane transporters is the dominant determinant: reduced secretion or increased reabsorption via URAT1, ABCG2, GLUT9, and related carriers elevates the urate pool. Sustained hyperuricaemia is the necessary upstream state for monosodium urate crystal formation.
Show evidence (2 references)
"Hyperuricemia is the result of increased production and/or underexcretion of uric acid."
Establishes the two converging upstream mechanisms of hyperuricaemia (overproduction and underexcretion) that define this trigger node. Evidence source is OTHER because this is a systematic review synthesizing multiple study types.
"Dysregulation of xanthine oxidoreductase (XOD), the enzyme that catalyzes uric acid biosynthesis primarily in the liver, and urate transporters that reabsorb urate in the renal proximal tubules (URAT1, GLUT9, OAT4 and OAT10) and secrete urate (ABCG2, OAT1, OAT3, NPT1, and NPT4) in the renal..."
Directly identifies dysregulated urate biosynthesis (XOD) and transporter handling (URAT1, ABCG2) in kidney and gut as the major cause of hyperuricaemia, supporting the overproduction/underexcretion model and the named transporters in the trigger description.
MSU Crystal Deposition
amplifier
Once serum urate exceeds its saturation point, monosodium urate supersaturates and nucleates into needle-shaped MSU crystals that deposit in and around joints and periarticular tissues. Crystal deposition is the pivotal step that converts the metabolic state of hyperuricaemia into a tissue lesion capable of provoking inflammation, and accumulated deposits seed both acute flares and chronic tophi.
Downstream
-
NLRP3 Inflammasome Activation
Show evidence (2 references)
"Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition."
Establishes MSU crystal deposition as the defining lesion of gout, the step that links hyperuricaemia to downstream inflammation. Evidence source is OTHER because this is an authoritative review (Nature Reviews Disease Primers).
"Elevated serum urate level (hyperuricaemia) is the major risk factor for MSU crystal deposition and development of gout."
Directly connects the upstream hyperuricaemia trigger to MSU crystal deposition, supporting the causal edge into this node. Evidence source is OTHER because this is a review.
NLRP3 Inflammasome Activation
central effector
Deposited MSU crystals are phagocytosed by resident and recruited macrophages and act as a danger signal that engages the caspase-1-activating NLRP3 inflammasome. Inflammasome assembly activates caspase-1, which cleaves pro-IL-1 beta into bioactive IL-1 beta (and IL-18). This is the central effector step that transduces an inert crystal deposit into a potent pro-inflammatory cytokine signal, and is conserved across disorders producing MSU crystals.
Used by disorders
Gout
as Inflammasome Activation
Downstream
-
IL-1-Driven Neutrophilic Inflammation
Show evidence (2 references)
"Here we show that MSU and CPPD engage the caspase-1-activating NALP3 (also called cryopyrin) inflammasome, resulting in the production of active interleukin (IL)-1beta and IL-18. Macrophages from mice deficient in various components of the inflammasome such as caspase-1, ASC and NALP3 are..."
Landmark mechanistic study (Martinon et al.) demonstrating that MSU crystals engage the caspase-1-activating NLRP3/NALP3 inflammasome in macrophages to produce active IL-1 beta, directly supporting the central effector step. Evidence source is IN_VITRO because the causal genetic dissection used cultured macrophages.
"Macrophage phagocytosis of UA activate NLRP3, lead to cytokines release, and ultimately, lead to chemoattract neutrophils and lymphocytes to the gout flare joint spot."
Review synthesis confirming that macrophage phagocytosis of urate activates NLRP3 and drives cytokine release that recruits neutrophils, linking this node to downstream neutrophilic inflammation. Evidence source is OTHER because this is a review.
IL-1-Driven Neutrophilic Inflammation
effector
Bioactive IL-1 beta released after inflammasome activation acts on IL-1 receptors on endothelial and resident cells to drive an acute inflammatory response, with massive recruitment and activation of neutrophils into the affected joint. Neutrophil influx and the resulting cytokine and chemokine amplification produce the intense pain, swelling, and erythema of the acute gout flare. IL-1 receptor signalling is required for the crystal-induced neutrophilic response.
Downstream
-
Recurrent and Chronic Tophaceous Gout
Show evidence (2 references)
"Moreover, an impaired neutrophil influx is found in an in vivo model of crystal-induced peritonitis in inflammasome-deficient mice or mice deficient in the IL-1beta receptor (IL-1R)."
Demonstrates in vivo that crystal-induced neutrophil influx depends on inflammasome and IL-1 receptor signalling, supporting IL-1 beta as the driver of acute neutrophilic inflammation. Evidence source is MODEL_ORGANISM because the in vivo data are from mouse peritonitis models.
"Macrophage phagocytosis of UA activate NLRP3, lead to cytokines release, and ultimately, lead to chemoattract neutrophils and lymphocytes to the gout flare joint spot."
Review evidence that the inflammasome-driven cytokine release chemoattracts neutrophils to the gout flare joint, supporting the neutrophil chemotaxis and inflammatory response processes at this node. Evidence source is OTHER because this is a review.
Recurrent and Chronic Tophaceous Gout
consequence
Repeated crystal-driven inflammatory flares present as acute, self-limiting monoarthritis. With persistent crystal deposition and unresolved hyperuricaemia, disease progresses to chronic inflammation, formation of tophi (organized aggregates of MSU crystals surrounded by inflammatory cells), and erosive damage to cartilage and bone with long-term functional impairment. This is the clinical phenotype of gout, the consequence of the conserved crystal-inflammation chain.
Show evidence (2 references)
"Gout typically presents as an acute, self-limiting inflammatory monoarthritis that affects the joints of the lower limb."
Describes the acute, self-limiting monoarthritis that is the clinical presentation of the recurrent gout flare, the consequence of this module. Evidence source is OTHER because this is a review.
"The clinical course of gout is initially characterized by acute self-limited joint inflammation, but long-standing disease is often associated with chronic inflammation followed by the development of erosive joint damage, which can result in long-term functional impairment."
Establishes the progression from acute flares to chronic inflammation and erosive joint damage with functional impairment, the chronic tophaceous consequence of the module. Evidence source is OTHER because this is a review synthesizing cellular and imaging studies.